pathways involving HIV infection and cancer metastasis make the CXCR4 receptor an attractive target for the development of therapeutic agents. Through scaffold hybridization of a few known CXCR4 antagonists, a series of novel aminopyrimidine derivatives was developed. Compound 3 from this new scaffold demonstrates excellent binding affinity with CXCR4 receptor (IC50 = 54 nM) and inhibits CXCL12 induced
CXCL12 / CXCR4轴在涉及HIV感染和癌症转移的众多致病途径中的重要作用使CXCR4受体成为治疗剂开发的有吸引力的靶标。通过几种已知的CXCR4拮抗剂的支架杂交,开发了一系列新型的
氨基嘧啶衍
生物。来自这种新支架的化合物3表现出与CXCR4受体的优异结合亲和力(IC 50 = 54 nM),并抑制CXCL12诱导的胞质
钙增加(IC 50 = 2.3 nM)。此外,化合物3具有良好的理化特性(MW 353,clogP 2.0,P
SA 48,pKa 6.7),并且对hERG和CYP同工酶(例如3A4、2D6)的抑制作用最小。总的来说,这些结果有力地支持了该新型支架的进一步优化以开发更好的CXCR4拮抗剂。